IMPRESS study shows continuing tyrosine kinase inhibitors after progression not effective
the ONA take:
According to new data presented at the European Society for Medical Oncology 2014 Congress in Madrid, Spain, patients with non-small cell lung cancer (NSCLC) that have developed resistance to gefitinib do not experience any statistically significant improvement in progression-free survival from continued treatment with gefitinib in combination with chemotherapy.
For the IMPRESS study, researchers identified 265 patients from 71 centers in Europe and the Asia Pacific region. Patients received chemotherapy plus either gefitinib or placebo. They found that the gefitinib group did not have a statistically significant improvement in progression-free survival versus the placebo group. It is too early to determine whether there was difference in overall survival, which the researchers say needs to be closely monitored in the future.
The researchers say that this study helps to determine the standard of treatment after a patient with NSCLC acquires resistance to epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) after an initial response. The results suggest that clinicians should not prescribe EGFR TKIs pub chemotherapy when patients with NSCLC have progressed after treatment with an EGFR TKI. The results were surprising to the researchers, as they believed an improvement in progression-free survival would be observed.
Patients resistant to gefitinib do not experience any significant improvement with gefitinib.
Patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in addition to chemotherapy, a phase III trial presented at the ESMO 2014 Congress has shown.
The IMPRESS trial is a randomised phase III study that compared continuation of gefitinib in addition to chemotherapy against chemotherapy alone in patients with lung cancer that carried mutations in the EGFR cell surface receptor.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|